<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>The Journal of School and University Medicine</JournalTitle>
      <Volume-Issue>Volume 6 Issue 4</Volume-Issue>
      <Season>October - December 2019</Season>
      <ArticleTitle>Depressive syndrome of young adult</ArticleTitle>
          <FirstName>Dr. Inna</FirstName>
          <FirstName>Sef lucrari Dr. Mirela</FirstName>
      <Abstract>BACKGROUND : Major depressive syndrome is commonly encountered in young people and can have significant consequences, leading to suicide, in severe forms.&#13;
AIMS : The study aimed to evaluate the therapeutic effectiveness and clinical tolerability of drug therapy in relation to its association with psychotherapy in young people diagnosed with depressive syndrome.&#13;
MATERIALS AND METHODS : The study includes 39 participants between the ages of 19 and 23, who were diagnosed with major depressive episode and treated in the specialized outpatient clinic from October 2017 to December 2018, following a well-established protocol.&#13;
RESULTS : After 12 weeks, 71% of the patients who benefited from the combination of the drug treatment with the psychotherapeutic one had the improvement of the specific symptomatology. Of those who only followed fluoxetine therapy, 61% of them made visible progress.&#13;
CONCLUSIONS : Combining pharmacological treatment with psychotherapy is the safest and most effective therapy for depressive patients.</Abstract>
      <Keywords>depressive syndrome, young adult</Keywords>
        <Abstract>https://revista-medicina-scolara.ro/ubijournal-v1copy/journals/abstract.php?article_id=9292&amp;title=Depressive syndrome of young adult</Abstract>
        <References>TADS Team. The Treatment for Adolescents with Depression Study (TADS). Long term effectiveness and safety outcomes. Archives of General Psychiatry. 2007; 64:1132-1144&#13;
	Jans T, Vloet TD, Taneli Y, Wanke A. Suicide and self-harming behaviour. In Rey JM (ed). IACAPAP e-textbook of Child and Mental Health, Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions; 2018.&#13;
	Rey JM, Bella-Awusah TT, Jing L. Depression in children and adolescents. In Rey JM (ed), IACAPAP e-textbook of Child and Mental Health, Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions; 2015.&#13;
	National Institute for Health and Clinical Excellence (NICE). Depression in children and young people: identification and management 2017&#13;
	Yakeley J, Johnston J, Adshead, G, Allison L. Medical psychotherapy. New York: Oxford University Press. 2016&#13;
	Klykylo W, Green W, Bowers R, Weston C, Jackson J. Green’s child and adolescent clinical psychopharmacology. 5th ed. Philadelphia: Lippincott Williams and; Wilkins; 2014.&#13;
	Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technology Assessment. 2008;12(14).&#13;
	Birmaher B, Brent D. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Depressive Disorders. Journal of the American Academy of Child and; Adolescent Psychiatry. 2007;46(11):1503-1526.&#13;
	Fand;ouml;cker M, Antel J, Grasemann C et al. BMC Psychiatry (2018) 18: 57.</References>